Default company panoramic image
Efb2f9c9 0074 4fa6 9a05 f5cfeb767320

iTeos Therapeutics

A spin off of the Ludwig Institute for Cancer Research and University of Louvain dedicated to the discovery of immunomodulators for cancer

  • Stage Product In Development
  • Industry Biotechnology
  • Location Louvain-la-Neuve, Ottignies-Louvain-la-Neuve, Walloon Region, Belgium
  • Currency EUR
  • Employees 0

Company Summary

iTeos is a private, biology-driven/ preclinical-stage company, that will leverage unique Ludwig Institute’s tumor immunology expertise to focus on discovery and development of first-in-class small molecule drugs that stimulate the immune system’s ability (immunomodulators) to attack cancer. Pipeline includes 1 program with a known human safety profile repurposed as immunomodulator, and 2 innovative druggable targets with preclinical validation


  • Default avatar
    Michel Detheux

    Michel Detheux headed during 8 years Euroscreen multidisciplinary team of 22 people dedicated to new target validation. He moved to bus dev and was involved in negotiation of deals with Cephalon, Novartis and Medarex. In 2006, he was promoted as Executive Director to create and manage Euroscreen FAST, a CRO for in vitro testing of drug candidates in preclinical development. He joined Ludwig Institute to create iTeos at the end of 2010

  • Default avatar
    Benoît Van den Eynde

    • B. Van den Eynde is the Director of the LICR Brussels Branch. He has an internationally recognized expertise in tumor immunology, with identification of some of the very first tumor antigens, antisense transcription and translation of alternative open-reading frames and the peptide splicing by the proteasome. His group was also the first one to demonstrate specific immunosuppressive mechanisms. He has received several awards during his career.


  • Default avatar
    Default avatar
    Timmermans & Fagard